To describe two infants with cholestatic jaundice treated with ursodeoxycholic acid (UDCA).
Case Summary
Two infants with cystic fibrosis (CF)-associated hepatobiliary disease, manifesting as cholestatic jaundice and elevated liver enzymes within the first 6 weeks of life, had improved biochemical indices of liver function following treatment with UDCA 20–40 mg/kg/d.
Discussion
To our knowledge, this is the first report of UDCA treatment in infants with CF-associated cholestatic jaundice. Infants and children require treatment with increased doses of UDCA to compensate for reduced intestinal absorption of bile acid and immaturity of the enterohepatic circulation.
Conclusions
UDCA appears to be a cost-effective treatment for CF-associated hepatobiliary disease in infants and children.
OppenheimerE.H., EsterlyJ.R.. Hepatic changes in young infants with cystic fibrosis. Possible relation to focal biliary cirrhosis. J Pediatr1975; 86: 683-9.
GaskenJ.K., WatersD.L.M., Howman-GilesR., De SilvaM., EarlJ.W., MartinH.C.O.Liver disease and common bile duct stenosis in cystic fibrosis. N Engl J Med1988; 318: 340-6.
ConnJ.A., StrongT.V., PicciottoM.R., NairnA.C., CollinsF.S., FitzJ.G.. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gut1993; 105: 1857-64.
6.
PouponR.E., PouponR.. Ursodeoxycholic acid for the treatment of cholestatic jaundice. Prog Liver Dis1992; 10: 219-38.
7.
MackD.R., TraystmanM.D., ColomboJ.L., SammutP.H., KaufmanS.S., VanderhoofJ.A.Clinical denouement and mutation analysis of patients with cystic fibrosis undergoing liver transplantation for biliary cirrhosis. J Pediatr1995; 127: 881-7.
van de MeebergP.C., van ErpecumK.J., van Berge-HenegouwenG.. Therapy with ursodeoxycholic acid in cholestatic liver disease. Scand J Gastroenterol1993; 28(suppl 200): 15-20.
10.
StrandvikB., LindbladA.. Cystic fibrosis. Is treatment with ursodeoxycholic acid of value?Scand J Gastroenterol1994; 29(suppl 204): 65-7.
11.
CottingJ., LentzeM.J., ReichenJ.. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut1990; 31: 918-21.
12.
ColomboC., CrosignaniA., AssaissoM., BattezzatiP.M., PoddaM., GiuntaA.Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose response study. Hepatology1992; 16: 924-30.
13.
ColomboC., SetchellK.D.R., PoddaM., CrosignaniA., RodaA., CurcioL.The effects of ursodeoxycholic acid therapy in liver disease associated with cystic fibrosis. J Pediatr1990; 117: 482-9.
14.
GalabertC., MontetJ.C., LengrandD., LecuireA., SottaC., FigarellaC.Effects of ursodeoxycholic acid on liver disease in patients with cystic fibrosis and chronic cholestasis. J Pediatr1992; 121: 138-41.
ColomboC., BattezzattiP.M., PoddaM., BettinardiN., GiuntaA. the Italian group for the study of ursodeoxycholic acid in cystic fibrosis. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology1996; 23: 1484-90.
17.
LepageG., ParadisK., LacailleF., SénéchalL., RoncoN., ChampagneJ.Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr1997; 130: 52-8.
18.
HofmannA.F.. Defective biliary secretion during total parenteral nutrition: probable mechanisms and possible solutions. J Pediatr Gastroenterol Nutr1995; 20: 376-90.
19.
SokolR.J.. Medical management of the infant or child with chronic liver disease. Semin Liver Dis1987; 7: 155-67.
20.
FrimanS., SvanvikJ.. A possible role of ursodeoxycholic acid in liver transplantation. Scand J Gastroenterol1994; 29(suppl 204): 62-4.
21.
NittonoH., TokitoA., HayashiM., WatanabeT., ObinataK., NakatsuN.Ursodeoxycholic acid therapy in treatment of biliary atresia. Biomed Pharmacother1989; 43: 37-41.
22.
ParadisK., El ArabN., YousefI., LacailleF., SchreiberR., LevyE.Use of ursodeoxycholic acid in children with cholestatic liver disease (abstract). Hepatology1993; 18: 301A.
23.
van Berge HenegouwenG.P., van HoekB., de GrootJ., MatemS., StockbrüggerR.W. eds. Cholestatic liver diseases: new strategies for prevention and treatment of hepatobiliary and cholestatic liver disease. Proceedings of the 75th Falk Symposium, Maastricht, The Netherlands, April 22-23, 1994. Dordrecht, UK: Kluwer Academic Press, 1994: 154-63.
24.
JohnsonC.E., NesbittJ.. Stability of ursodiol in an extemporaneously compounded oral liquid. Am J Health-Syst Pharm1995; 52: 1798-800.
